Pilot Study of Ivonescimab in Advanced/Metastatic Cutaneous Angiosarcoma
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT07655570
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Cutaneous Angiosarcoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ivonescimab — DRUGGiven by IV
Study Details
This is a pilot study evaluating the efficacy and safety of ivonescimab in subjects with advanced or metastatic cutaneous angiosarcoma who have previously been treated with taxane-based chemotherapy.
Key Dates
- Start date
- Nov 30, 2026
- Status verified
- Jun 2026
- Primary completion
- May 11, 2027
- Completion
- May 11, 2029
Study Design
- Enrollment
- 10 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment with IvonescimabParticipants will be treated with ivonescimab (20 mg/kg IV on Day 1 Q3W). The treatment will be repeated every 3 weeks until progressive disease (PD), intolerable toxicity, initiation of new anti-tumor therapy, withdrawal of informed consent, lost to follow-up, completion of therapy, death, or any other investigator-determined reasons for treatment discontinuation (whichever occurs first).
Primary Outcome Measure
Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]
Central Contacts
- Michael Nakazawa, MD713-785-7017
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UT MD Anderson | Houston | Texas | 77030 | Michael Nakazawa, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
By research site